Omicron: A new face of <scp>COVID</scp>‐19 pandemic

Khan, Amjad; Bibi, Salma; Kanwal, Hafsa; Umm-e-Kalsoom,; Hussain, Hidayat

doi:10.1002/hsr2.526

Cited by 5 publications

(5 citation statements)

References 3 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, it was observed that respiratory symptoms decreased significantly in hospitalized patients in the Omicron period compared to the nonvariant period. This result was consistent with studies indicating that Omicron caused more severe inflammation in the upper respiratory tract than in the lung 16,17 . In contrast, a US study in the first period of the Omicron wave reported increased respiratory symptoms in hospitalized patients in Omicron compared to nonvariant 7 .…”

Section: Discussionsupporting

confidence: 90%

“…This result was consistent with studies indicating that Omicron caused more severe inflammation in the upper respiratory tract than in the lung. 16,17 In contrast, a US study in the first period of the Omicron wave reported increased respiratory symptoms in hospitalized patients in Omicron compared to nonvariant. 7 Unlike the nonvariant period, detecting RSV, hMPV, and influenza coinfections in children with Omicron infections may have contributed to their results.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

The diversity in the clinical features of children hospitalized with COVID‐19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV‐2: Caution for neurological symptoms in Omicron variant

Şahin

Karadağ‐Öncel

Buyuksen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

Since the COVID-19 pandemic began, various severe acute respiratory syndrome coronavirus 2 variants have been identified with different characteristics than the nonvariant strain. We retrospectively evaluated the demographic and clinical differences in the cohort of hospitalized COVID-19 children (1 month-18 years old) between March 11, 2020, and September 31, 2022, by the time the variants identified in our country predominate. Bonferroni post hoc analysis was performed to compare the differences between the periods. Of the 283 children in this study, 142 (50.2%) were females. The median age was 36 (interquartile range [IQR]: 7-132) months. Sixty-three (22.2%) patients were hospitalized in the nonvariant period, 24 (8.5%) in the Alpha period, 93 (32.9%) in the Delta period, and 103 (36.4%) in the Omicron period. Fever was the most common symptom in all groups, with no statistically significant differences (p = 0.25). In the Omicron period, respiratory and gastrointestinal symptoms decreased, and neurological symptoms increased significantly compared to other periods: [respiratory symptoms; nonvariant (65.1%) vs. Omicron (41.7%), (p = 0.024)], [gastrointestinal symptoms; Delta (41.9%) vs. Omicron (22.3%), (p = 0.018), [neurological symptoms; Delta (14.5%) vs. Omicron (31.1%), (p = 0.03]. Altered mental status and seizures were more common during the Omicron period compared to the pre-Omicron (nonvariant, Alpha, and Delta) period (p = 0.017 and p = 0.005, respectively). Although the main symptoms in children with COVID-19 were fever and respiratory symptoms, an increase in severe neurological manifestations was seen throughout the Omicron variant period.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 89%

The diversity in the clinical features of children hospitalized with COVID‐19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV‐2: Caution for neurological symptoms in Omicron variant

Şahin

Karadağ‐Öncel

Buyuksen

et al. 2023

Journal of Medical Virology

View full text Add to dashboard Cite

show abstract

“…Одновременно наблюдался рост активности циркуляции сезонных респираторных вирусов, вирусов гриппа и вариантов SARS-CoV-2, объединённых под названием Омикрон. Особенности циркулирующих генотипов Омикрона обусловили схожесть клинической симптоматики COVID-19 с другими ранее известными респираторными вирусными инфекциями, существенно более низкую частоту развития тяжёлых вариантов течения вместе с высокой степенью вовлечения в эпидемический процесс детского населения [2]. Вместе с этим на фоне большого числа лёгких форм и общих подходов к терапии ОРВИ различной этиологии у детей [3,4] существенно снизилась доля случаев с применением лабораторной диагностики.…”

Section: Introductionunclassified

The effect of topical drugs on the course of ARVI in children in modern conditions

Ruzhentsova,

Garbuzov,

Meshkova

et al. 2024

Immunopathol Allergol Infectol

View full text Add to dashboard Cite

The purpose of the study. To evaluate the results of using a drug based on benzidamine hydrochloride in the treatment regimens of acute respiratory viral infections in children today. Materials and methods. The study included 875 children aged 3 to 18 years with acute respiratory viral infections, which occurred in mild or moderate forms, and were treated on an outpatient basis. During the non-interventional study, a retrospective analysis of information from medical records was made. The main group included 318 children who were recommended therapy with a drug based on benzidamine hydrochloride, the comparison group included 557 children who received other topical drugs. Results. Recovery was statistically significantly earlier in the group receiving benzidamine hydrochloride: from the moment of initiation of therapy, the disease period in the main group was 6.78±1.72 days, while in the comparison group it was 1.34 days longer – 8.12±3.32. It was found that benzidamine hydrochloride significantly reduces the period of tickling and sore throat from 5.10±1.38 in the comparison group to 4.08±1.41 in the main group, hyperemia of the posterior pharyngeal wall – from 8.11±3.27 in the comparison group to 6.68±1.6 days in the main group, hyperemia of the tonsils – from 7.85±1.84 in the comparison group to 6.86±1.77 in the main group. Relief of dry cough was recorded in the group receiving benzidamine hydrochloride at 4.23±1.66 days, and in the group where other drugs were used – at 4.64±1.85 days. According to other indicators, no significant differences were found between the compared groups. Conclusion. The administration of a drug based on benzidamine hydrochloride as part of complex therapy statistically significantly, on average, reduces the total duration of acute respiratory viral infections in children from 3 years old by 1.34 days, reduces the period of tickling and sore throat by 1.08 days; by 1.43 days – visual manifestations of pharyngitis, by 1.0 days – tonsillitis; reduces the duration of dry cough.

show abstract

“…The WHO received reports of a total of 6.09 million fatalities and 472.8 million confirmed cases up through March 2022 6 . In Syria, the number of confirmed cases and deaths were 55,595 and 3000, respectively 6,7 . The clinical signs and symptoms of COVID‐19 might vary from an asymptomatic infection to a serious sickness needing hospitalization and oxygen support 8 .…”

Section: Introductionmentioning

confidence: 99%

“…6 In Syria, the number of confirmed cases and deaths were 55,595 and 3000, respectively. 6,7 The clinical signs and symptoms of COVID-19 might vary from an asymptomatic infection to a serious sickness needing hospitalization and oxygen support. 8 Patients with mild to moderate COVID-19 might experience fever, cough, sore throat, diarrhea, fatigue, fatigue, headache, muscle or joint pain, and loss of smell and taste.…”

Section: Introductionmentioning

confidence: 99%

Knowledge, attitudes, and practices related to COVID‐19 infection, related behavior, antibiotics usage, and resistance among Syrian population: A cross‐sectional study

Swed

Shoib²,

Almoshantaf

et al. 2022

Health Science Reports

View full text Add to dashboard Cite

Background and Aims Antibiotic resistance is seen as a worldwide health risk as a result of the overuse of antibiotics. Many countries noted that antibiotic usage was high during the COVID‐19 pandemic. The purpose of this study is to evaluate Syrians' knowledge, attitudes, and practice about the use of antibiotics and antibiotic resistance during the COVID‐19 epidemic. Methods A cross‐sectional study was conducted using an online questionnaire to collect the data from the Syrian population from February 5 to March 4, 2022. Syrians 18 years or older all over the world were able to participate in this study. A convenience snowball sampling method was used. SPSS version 20.0 was used to analyze the data. To examine the results, binominal logistic regression was used. Statistical significance was defined as a p < 0.05. Results Out of 2406 respondents, 60.2% knew that transmission of COVID‐19 could occur even if the patient has not developed any symptoms, and 91.6% were able to recognize the main clinical symptoms of COVID‐19. There was a statistically significant difference between male and female knowledge of COVID‐19 ( p = 0.002), with males having 3.78 ± 2.1 (2.7–3.87) and females scoring 3.93 ± 2.3 (3.7–4.1). Newly graduated students have more knowledge of COVID‐19 than other subtypes of Job ( p = 0.0001), and those with medical practice are more knowledgeable than those without ( p = 0.0001). Only 16.6% answered that taking antibiotics would not speed up the recovery from all the infections. 65.3% answered correctly that misuse of antibiotics could cause antibiotic resistance. Conclusion Our study concluded that the Syrian population demonstrated good knowledge of COVID‐19 and moderate acceptance of the new norm. Knowledge regarding antibiotic use and resistance and practice of preventive measures was poor, which can encourage the health authorities to develop community education programs to increase public awareness of the usage of antibiotics and safety protocols during the COVID‐19 pandemic.

show abstract

Omicron: A new face of COVID‐19 pandemic

Cited by 5 publications

References 3 publications

The diversity in the clinical features of children hospitalized with COVID‐19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV‐2: Caution for neurological symptoms in Omicron variant

The diversity in the clinical features of children hospitalized with COVID‐19 during the nonvariant, Alpha (B.1.1.7), Delta (B.1.617.2), and Omicron (B.1.1.529) variant periods of SARS CoV‐2: Caution for neurological symptoms in Omicron variant

The effect of topical drugs on the course of ARVI in children in modern conditions

Knowledge, attitudes, and practices related to COVID‐19 infection, related behavior, antibiotics usage, and resistance among Syrian population: A cross‐sectional study

Contact Info

Product

Resources

About